Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Research Report: Forecast (2025-2030)

Market Definition

Colorectal cancer (CRC) is a type of cancer that often begins as polyps, which are abnormal growths in the colon or rectum. If not addressed, it has the potential to spread to other areas of the body. As one of the most common cancers globally, colorectal cancer boasts a high survival and treatment success rate when identified in its early stages.

Market Insights & Analysis: Global Colorectal Cancer (CRC) Diagnostics and Treatments Market (2025-30)

The Global Colorectal Cancer (CRC) Diagnostics and Treatments Market size was valued at around USD10.89 Billion in 2024 and is projected to reach USD16.89 Billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 7.6% during the forecast period, i.e., 2025-30.

This market expansion is linked to several factors. The market for colorectal cancer diagnosis and treatment is being greatly boosted by the growth of specialty cancer hospitals around the world. For instance, to enhance local cancer care in Kerala, India opened a six-story cancer specialty block at Ernakulam General Hospital in October 2023. The building has 105 beds contemporary amenities, an intensive care unit, and a chemotherapy unit. To address the growing need for specialized CRC care in the area KLE Society in Belagavi, opened a state-of-the-art 300-bed cancer hospital in December 2024. The facility offers everything from robotic surgery to bone marrow transplants. Herb Chambers donated USD 100 million to Massachusetts General Hospital (USA) in December 2024 so that they could construct a new tower that would allow patients, including those with colorectal cancer to receive more centralized cancer care services.

*Boost strategic growth with in-depth market analysis - Get a free sample preview today!

In the United States 2024, Cardinal Health paid USD 1.12 billion to acquire Integrated Oncology Network, expanding its oncology network to over 100 healthcare providers in 10 states. This move increased the accessibility of specialized oncology services for patients with colorectal cancer. These noteworthy advancements show a global dedication to enhancing cancer care systems which will boost the markets for CRC diagnosis and treatment.

For its early detection & intervention, CRC is being diagnosed by government-led screening programs. This has boosted the global market. To enhance its screening for populations with low screening rates, particularly those aged 45 to 75, the Center for Disease Control and Prevention started a cooperative agreement in the United States in 2024. The goal of this program is to collaborate with primary care clinics and health systems to create evidence-based interventions for this population. Similarly, Taiwan’s Health Promotion Administration started implementing free biennial fecal immunochemical testing (FIT) for people aged 45–74 years in January 2025.  This is to promote early diagnosis and lower the mortality rates associated with colorectal cancer. By encouraging proactive screening methods, these government policies support global efforts to prevent colorectal cancer, which in turn drives demand for diagnostics and treatments.

New opportunities for market consideration have been presented by the home testing kit that will boost the industry’s growth. A significant shift has occurred in recent years toward non-invasive test kits that enable the general public to perform the test at home with ease. This trend is majorly growing in North America due to the increased demand for at-home testing. Cologuard Plus is one such kind of FDA-approved test kit developed by Exact Sciences that allows people to collect stool samples & test them for the early detection of colorectal cancer (CRC). The rationale for using the kit includes accuracy and a growing understanding of the importance of early cancer detection. Home testing kits will help increase the rate of early CRC detection, which will reduce healthcare costs and improve patient outcomes in CRC management. This contributes to influencing market dynamics and generating significant growth shortly.

Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Driver:

High Ubiquity of Colorectal Cancer Driving Demand – Globally, colorectal cancer is a major health concern. 930,000 people died and 10. 9 million new cases were reported worldwide in 2020. The number of cases is expected to increase to 32. 2 million by 2040, with 12. 6 million expected deaths. The disease is most common in countries with high or extremely high HDI. With 10% of cases worldwide, it is the second most common cause of cancer-related deaths and the third most common type of cancer overall. Different geographic prevalence rates indicate that colorectal cancer (CRC) is most common in Australia, New Zealand, and Europe, while it is less common in some parts of Africa and Southern Asia.

These geographic disparities underscore the necessity for regional strategies in CRC management. In light of the increasing incidence of CRC, novel diagnostic technologies are being created. A recent innovation involves a small robot that can travel through the digestive tract and conduct 3D scans to facilitate improved early detection and treatment. The high incidence will drive the market growth throughout the forecast period and beyond.

Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Opportunity:

Rise of Personalized Medicine Providing Lucrative Opportunity – Personalized medicine has significant potential in the international colorectal cancer diagnostics and treatment market. Treating drugs by the genetic data of a specific patient, personalized medicine improves efficacy and reduces side effects. Targeted drugs by genetic tests provide enhanced survival for patients with CRC, according to research. For example, the identification of KRAS and NRAS mutations helps doctors recognize if a patient will be responsive to anti-EGFR drugs, thus becoming a more targeted and effective treatment.

In addition, biomarker-targeted immunotherapies such as checkpoint inhibitors have been highly effective in those with specific genetic profiles. Precision medicine has been discovered to permit earlier diagnosis by liquid biopsies, avoiding the use of invasive procedures. With the improvements in molecular diagnosis and genetic profiling, personalized therapy for CRC is evolving, leading to better patient outcomes and less unnecessary therapy.

Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Challenge:

Side Effects Caused by Treatments Creating Resistance – Treatment-related adverse effects of colorectal cancer are a serious concern that most often lead to drug resistance as well as less effectiveness of the drugs. Severe diarrhea, nausea, weakness, and immunocompromised are some common side effects that put patients at risk of infections. Toxicity in normal cells as a consequence of long-term chemotherapy can result in neurological and gastrointestinal symptoms. Research has identified that drug resistance in around 50% of metastatic CRC patients is observed a few months after therapy. One of the factors leading to drug resistance occurs because the body can repair the mutated cancer cells, and the drug becomes less effective. Cancer cells are sometimes able to change their morphology, which makes it even more difficult for treatments to reach them. Studies indicate that tumors will become increasingly resistant to the drug over time, hindering its ability to work. Developing other treatments is vital to overcome these challenges and maximize the survival chances of patients.

Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Trend:

Integration of Multiomics Approaches – The incorporation of multiomics strategies is shaping the global market. It integrates various omics to provide a more in-depth molecular understanding of colorectal cancer. The use of these approaches improves the ability to diagnose and personalize treatment for colorectal cancer by establishing new cancer biomarkers and therapeutic targets. The United States, Germany, and China have established themselves as researchers in this domain. For instance, a study published in Molecular Cancer demonstrated a multiomics-based blood test to provide high sensitivity when detecting early-stage CRC, including sensitivities of 80% for stage I and 89.2% for stage II.

The increasing emphasis on personalized medicine, combined with early detection of cancer, is driving their acceptance, making them a significant market trend.  These approaches help in identifying the best target therapies that will have little risks of side effects, which improves patient outcomes. Hence, it is easy to conclude that the multiomics approach will be critical to the future of CRC diagnosis and treatment.

Global Colorectal Cancer Diagnostics and Treatments Market (2025-30): Segmentation Analysis

The Global Colorectal Cancer (CRC) Diagnostics and Treatments Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2025–2030 at the global level. Based on the analysis, the market has been further classified as:

Based on Treatment:

• Chemotherapy
• Immunotherapy
• Surgery
• Targeted Therapy
• Others (Radiofrequency Ablation (RFA), etc.)

Based on the treatment, Chemotherapy leads the Global Colorectal Cancer (CRC) Diagnostics and Treatments Market. It holds approx. 50% share of the total market. This prominence stems from its thoroughly documented success in decreasing the size of tumors and enhancing overall survival, irrespective of the disease stage. Chemotherapy is employed worldwide, spanning from leading cancer facilities in North America to smaller for-profit clinics in Asia, usually as the first line of treatment or alongside other therapies. Treatment protocols such as FOLFOX are recognized choices because of their established effectiveness. Chemotherapy is prevalent due to its proven efficacy, versatility, and the continuous advancement of new chemotherapeutic drugs aimed at improving patient results.

Based on End-User:

• Hospitals
• Specialty Clinics
• Others (Ambulatory Surgery Centers, etc.)

Based on end-users, hospitals dominate the Global Colorectal Cancer (CRC) Diagnostics and Treatments Market. It holds approx. 42% of the total market. Several factors lead to this advantageous situation. Top hospitals are equipped with cutting-edge diagnostic resources such as gastroenterology labs, radiology departments, and oncology facilities to support CRC screening and timely identification. For instance, the Asian Institute of Gastroenterology performs 10,000 colonoscopies annually, which enables the early detection and intervention of CRC.

Furthermore, numerous governments have set up national CRC screening initiatives that primarily take place in hospitals to promote early detection and treatment. Moreover, the existence of specialized healthcare providers and collaborative healthcare services in hospitals creates a seamless patient journey from diagnosis to treatment, ensuring hospitals continuously dominate the market for CRC diagnostics and treatments.

Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Regional Projection

Geographically, the Global Colorectal Cancer (CRC) Diagnostics and Treatments Market expands across:

• North America
• South America
• Europe
• The Middle East & Africa
• Asia-Pacific

Out of them, North America leads the Global Colorectal Cancer (CRC) Diagnostics & Treatments Market. It holds approx. 40% share of the total market value. The growth of this region is driven by a well-developed healthcare infrastructure with sophisticated medical technology that provides timely and correct diagnoses. The high incidence of colorectal cancer within the Geocradle area identifies a need for therapeutic and diagnostic measures. The earlier detection and improved survival of patients are integral elements of public health services, such as a national screening program and campaign programs.

Furthermore, the location of large biotech and pharmaceutical firms leads to a general environment of ongoing research that translates into new and better treatments and diagnostic means for colorectal cancer. Collectively, these will maintain North America as the dominant worldwide market for the diagnosis and treatment of colorectal cancer.

Global Colorectal Cancer (CRC) Diagnostics and Treatments Industry Recent Developments 

• January 2025: Amgen Inc. got approval from the FDA to expand the label of its KRAS inhibitor Lumakras (sotorasib), opening up its use in colorectal cancer. With this, Lumakras can now be combined with another Amgen asset, the antibody Vectibix (panitumumab), to treat adult patients with metastatic disease who are carrying the G12C KRAS mutation.

Gain a Competitive Edge with Our Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Report

1. Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Report by Markntel Advisors provides a detailed & thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps business organizations to gain a holistic understanding of market dynamics & make informed decisions.
2. This report also highlights current market trends & future projections, allowing business organizations to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
3. Global Colorectal Cancer (CRC) Diagnostics and Treatments Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, business organizations can develop strategies to minimize risks & optimize their operations.